Phenotypes Associated with This Genotype

Genotype
MGI:4838317

• Allelic Composition: Pten^tm2.1Ppp/Pten^tm2.1Ppp; Tg(TPO-cre)1Shk/0
• Genetic Background: 129S1.Cg-Pten^tm2.1Ppp Tg(TPO-cre)1Shk

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:165293 )

• females have a reduced lifespan compared to males, with a mean survival age of 73 weeks compared to 83 weeks in males

• mutants start to show signs of illness starting after 1 year of age

endocrine/exocrine glands

thyroid gland hyperplasia ( J:165293 )

• enlarged thyroid

• ovariectomization of females results in reduced proliferative index of thyroids to a similar level seen in males

increased thyroid adenoma incidence ( J:165293 )

• 52% of females develop thyroid follicular adenomas between 8-12 months of age compared to 12% of males

increased thyroid carcinoma incidence ( J:165293 )

• 50% of the females and 35% of males over one year of age develop invasive and often metastatic thyroid follicular carcinomas

homeostasis/metabolism

decreased thyroid-stimulating hormone level ( J:165293 )

• aging mice exhibit suppression of thyroid-stimulating hormone

increased thyroxine level ( J:165293 )

• thyroxine levels are slightly, but significantly, increased in all mice with adenomas

neoplasm

increased thyroid adenoma incidence ( J:165293 )

• 52% of females develop thyroid follicular adenomas between 8-12 months of age compared to 12% of males

increased thyroid carcinoma incidence ( J:165293 )

• 50% of the females and 35% of males over one year of age develop invasive and often metastatic thyroid follicular carcinomas

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
thyroid gland follicular carcinoma		DOID:3962	OMIM:188470	J:165293